Literature DB >> 8264632

Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function.

M R Johnson1, J E DeClue, S Felzmann, W C Vass, G Xu, R White, D R Lowy.   

Abstract

The NF1 gene, which is altered in patients with type 1 neurofibromatosis, has been postulated to function as a tumor suppressor gene. The NF1 protein product neurofibromin stimulates the intrinsic GTPase activity of active GTP-bound Ras, thereby inactivating it. Consistent with a tumor suppressor function, we have found that the introduction of NF1 in melanoma cell lines that are deficient in neurofibromin inhibited their growth and induced their differentiation. In addition, overexpression of neurofibromin in NIH 3T3 cells was growth inhibitory but did not alter the level of GTP.Ras in the cells. Transformation by v-ras, whose protein product is resistant to GTPase stimulation by neurofibromin, was inhibited in a cell line overexpressing neurofibromin, while transformation by v-raf was not altered. The results demonstrate that NF1 is a tumor suppressor gene that can inhibit Ras-dependent growth by a regulatory mechanism that is independent of neurofibromin's ability to stimulate Ras GTPase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8264632      PMCID: PMC358413          DOI: 10.1128/mcb.14.1.641-645.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  34 in total

1.  Activation of the MAP kinase pathway by the protein kinase raf.

Authors:  L R Howe; S J Leevers; N Gómez; S Nakielny; P Cohen; C J Marshall
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

2.  Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling.

Authors:  M Duchesne; F Schweighoffer; F Parker; F Clerc; Y Frobert; M N Thang; B Tocqué
Journal:  Science       Date:  1993-01-22       Impact factor: 47.728

3.  Differential regulation of cellular activities by GTPase-activating protein and NF1.

Authors:  N al-Alawi; G Xu; R White; R Clark; F McCormick; J R Feramisco
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

4.  Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.

Authors:  L B Andersen; J W Fountain; D H Gutmann; S A Tarlé; T W Glover; N C Dracopoli; D E Housman; F S Collins
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

5.  Neurofibromatosis type 1 gene mutations in neuroblastoma.

Authors:  I The; A E Murthy; G E Hannigan; L B Jacoby; A G Menon; J F Gusella; A Bernards
Journal:  Nat Genet       Date:  1993-01       Impact factor: 38.330

6.  Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.

Authors:  E Legius; D A Marchuk; F S Collins; T W Glover
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

7.  Differences in the interaction of p21c-Ha-ras-GMP-PNP with full-length neurofibromin and GTPase-activating protein.

Authors:  D DiBattiste; M Golubic; D Stacey; A Wolfman
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

8.  Analysis of the neurofibromatosis type 1 (NF1) GAP-related domain by site-directed mutagenesis.

Authors:  D H Gutmann; M Boguski; D Marchuk; M Wigler; F S Collins; R Ballester
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

9.  Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.

Authors:  P Dent; W Haser; T A Haystead; L A Vincent; T M Roberts; T W Sturgill
Journal:  Science       Date:  1992-09-04       Impact factor: 47.728

10.  Molecular characterization of a 17q11.2 translocation in a malignant schwannoma cell line.

Authors:  J E Reynolds; J A Fletcher; C H Lytle; L Nie; C C Morton; S R Diehl
Journal:  Hum Genet       Date:  1992-12       Impact factor: 4.132

View more
  23 in total

1.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

2.  Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles.

Authors:  P Morcos; N Thapar; N Tusneem; D Stacey; F Tamanoi
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.

Authors:  L S Sherman; R Atit; T Rosenbaum; A D Cox; N Ratner
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

Review 4.  Neurofibromatosis and related tumors. Natural occurrence and animal models.

Authors:  V M Riccardi; J E Womack; T Jacks
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 5.  Aberrant function of the Ras signal transduction pathway in human breast cancer.

Authors:  G J Clark; C J Der
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

Review 6.  Molecular genetics of neurofibromatosis type 1 (NF1).

Authors:  M H Shen; P S Harper; M Upadhyaya
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

7.  Structural analysis of the GAP-related domain from neurofibromin and its implications.

Authors:  K Scheffzek; M R Ahmadian; L Wiesmüller; W Kabsch; P Stege; F Schmitz; A Wittinghofer
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 8.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling.

Authors:  D T Denhardt
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

Review 9.  Molecular biology of pediatric gliomas.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

10.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.